Zea Biosciences Signs Exclusive License Agreement with the University of Pennsylvania for Hemophilia A, B Oral Tolerance Programs
Strategic partnership accelerates the development of biologic products for addressing oral tolerance in Hemophilia A and B patients.
WALPOLE, Mass., March 28, 2023 /PRNewswire-PRWeb/ -- Zea Biosciences, a Boston-based biopharmaceutical company with a new platform for biologics and vaccine development, has signed an exclusive license agreement with the University of Pennsylvania and the University of Florida. The strategic partnership will aim to rapidly develop and scale potential products for clinical development to address the issue of oral tolerance in Hemophilia A and B patients.
"We are very excited about this collaboration with the University of Pennsylvania, as it is a beneficial relationship for both of our organizations," said Jim Wilson, founder of Zea Biosciences. "Long term, the results from this will allow for an exciting new way of developing biologics and fundamentally change the way manufacturing and global supply chains are managed; the hope is we can make a less expensive product and offer that benefit for everyone, providing wellness across the world."
"We are thrilled to be advancing the revolutionary work from the labs of Dr. Henry Daniell and Dr. Roland Herzog (formerly of the University of Florida) through this agreement," says Dr. Mark S. Wolff, Dean of Penn Dental Medicine, where Dr. Daniell is the W.D. Miller Professor in the Department of Basic & Translational Sciences. "His plant-based, protein-production platform has tremendous potential to change the way a whole host of therapeutics are produced and delivered."
Dr. Daniell developed this platform to produce specific proteins of interest for a wide range of applications, which are both cost effective and shelf stable.
Charles Legg, CEO of Zea Biosciences, stated, "This is a great step forward for Zea and we look forward to working with the patient communities and the University of Pennsylvania. Zea is passionate about addressing significant critical, unmet health needs in the near term, but also enabling a platform that may just change the game in addressing important health issues around the world."
About Zea Biosciences:
Boston-based Zea Biosciences exists to provide access to reliable, important medicines to address critical unmet medical needs and enable healthier communities. As a plant biotechnology platform focused on identifying, producing, and growing highly effective drugs, we are on a mission to unlock a better future for as many people as possible. Zea's motto: Unlock the possible. To learn more, please visit us at http://www.zeabio.com.
About Penn Dental Medicine:
Founded in 1878, the University of Pennsylvania School of Dental Medicine (Penn Dental Medicine) ranks among the nation's leaders in oral health education, research, and patient care. Penn Dental Medicine has a rich history as a research-intensive institution and continues to be international leaders in the generation of new knowledge and treatment modalities to improve oral and overall health. As one of 12 schools within the larger urban campus of the University of Pennsylvania, Penn Dental Medicine engages in a depth of interdisciplinary study and research across other disciplines. The School's educational programs include a four-year DMD program; postgraduate study in all the major clinical specialties as well as general dentistry; advanced graduate degree programs; and the Program for Advanced Standing Students in which foreign-trained dentists earn a DMD. In addition, the School is a major provider of oral health care within the Philadelphia region through its care centers and community-care sites.
Media Contact
Brooke Greenwald, Cornerstone Communications, LTD, 240-301-3600, [email protected]
SOURCE Cornerstone Communications, LTD
Share this article